Funding for this research was provided by:
Multiple Sclerosis Society of Canada
Canadian Institutes of Health Research
Received: 8 January 2018
Accepted: 22 March 2018
First Online: 19 April 2018
Ethics approval and consent to participate
: All healthy control and multiple sclerosis participants provided informed consent in accordance to the declaration of Helsinki, as part of a protocol approved by the Ethics Review Board (ERB) of the Montréal Neurological Institute (MNI).
: Not applicable.
: A.B.-O receives research funding from the Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, National Multiple Sclerosis Society, Melissa and Paul Anderson Chair in Neuroinflammation.A.B.-O has participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from Atara Biotherapeutics, Biogen Idec, Celgene/Receptos, Genentech/Roche, GlaxoSmithKline, Medimmune, Merck/EMD Serono, Novartis, Sanofi-Genzyme.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.